Haemophilus influenzae type b (Hib) Vaccine

Haemophilus influenzae type b (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in children aged less than 5 years. Hib have caused million cases of serious disease and 386 000 deaths in young children. Hib immunization is recommended by WHO.


BioNet has developed Hib vaccine using new fermentation and conjugation technologies. This Hib technology has been transferred to various manufacturers. PentaBio, a pentavalent vaccine produced by Bio Farma from Indonesia, using this technology is commercially available and has been pre-qualified by the World Health Organization for United Nations supplies.


More information available at:
http://www.who.int/immunization_standards/vaccine_quality/pq_287_dtphepbhib_10dose_vial_biofarma/en/